Used as a potent and selective inhibitor of autotaxin (ATX), a key enzyme involved in the production of lysophosphatidic acid (LPA). LPA plays a significant role in various pathological processes including inflammation, fibrosis, and cancer progression. Autotaxin-IN-3 is primarily applied in research settings to study ATX-mediated signaling pathways and to evaluate the therapeutic potential of ATX inhibition in diseases such as idiopathic pulmonary fibrosis, liver fibrosis, and certain cancers. It has shown efficacy in reducing LPA levels in biological samples and in vivo models, making it a valuable tool compound for preclinical studies targeting the LPA pathway. Its selectivity and pharmacokinetic properties support its use in proof-of-concept experiments for drug development.